Whole-genome sequencing does not increase downstream healthcare spending outside of the sequencing costs.
Experts at the ACCC 44th Annual Meeting & Cancer Center Business Summit identified some of the largest drivers of change and rapidly evolving initiatives in oncology care, including costs of care and precision medicine initiatives.
Targeted next-generation sequencing may accurately estimate tumor mutation burden in NSCLC, which may further shed light on the likelihood of benefit from immune checkpoint inhibitors in individual patients.
A commonly used gene expression profile test for predicting breast cancer recurrence proves to be less cost-effective in a real-world setting, according to research published in the Journal of Clinical Oncology.
High levels of a specific enzyme are linked with lower survival rates in patients with multiple myeloma, according to a new study.
The US Food and Drug Administration has approved a next-generation sequencing assay that may be used as a companion diagnostic for therapy selection for solid tumors.
A recent study found that a significant number of patients with multiple myeloma harbor potentially actionable oncogenic molecular alterations, prompting a need for novel precision medicine approaches.
Investigating genetic variations within a primary tumor and additional diversity found in tumor DNA in the bloodstream could help guide and improve treatment choices in patients with gastroesophageal adenocarcinoma.
A recent study showed that after performing next-generation sequencing of non-small cell lung cancer gene panels, actionable mutations were identifiable in 65% of cases with available targeted therapeutic options.
The 70-gene signature assay for early breast cancer provides physicians with actionable information and may be associated with adjuvant therapy decisions.